Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Foamix Pharma Ord (FOMX)

Foamix Pharma Ord (FOMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 208,264
  • Shares Outstanding, K 61,254
  • Annual Sales, $ 3,600 K
  • Annual Income, $ -74,160 K
  • 60-Month Beta 1.57
  • Price/Sales 59.29
  • Price/Cash Flow N/A
  • Price/Book 3.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.33
  • Number of Estimates 1
  • High Estimate -0.33
  • Low Estimate -0.33
  • Prior Year -0.26
  • Growth Rate Est. (year over year) -26.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.66 +28.20%
on 10/25/19
4.35 -21.61%
on 11/08/19
+0.25 (+7.99%)
since 10/18/19
3-Month
2.53 +34.78%
on 10/07/19
4.35 -21.61%
on 11/08/19
+0.51 (+17.59%)
since 08/20/19
52-Week
1.97 +73.10%
on 07/26/19
4.48 -23.88%
on 03/08/19
-0.38 (-10.03%)
since 11/20/18

Most Recent Stories

More News
Foamix Announces Enrollment Completion of Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (Foamix or the Company), a specialty pharmaceutical company, today announced the completion of Phase 2 clinical trial enrollment of FCD105 for the treatment of...

FOMX : 3.41 (+0.29%)
URGENT NEWS: Monteverde & Associates PC Announces an Investigation of FOAMIX PHARMACEUTICALS LTD - FOMX

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Foamix Pharmaceuticals,...

FOMX : 3.41 (+0.29%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Menlo Therapeutics Inc. with Foamix Pharmaceuticals Ltd. is Fair to MNLO Shareholders

The following statement is being issued by Levi & Korsinsky, LLP:

MNLO : 4.07 (-0.97%)
FOMX : 3.41 (+0.29%)
SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Foamix Pharmaceuticals Ltd. ("FOMX" or the "Company") (NASDAQ: FOMX) in connection...

FOMX : 3.41 (+0.29%)
MNLO : 4.07 (-0.97%)
FOAMIX ALERT: Bragar Eagel & Squire, P.C. Investigates Proposed Sale of FOMX and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) breached their fiduciary...

FOMX : 3.41 (+0.29%)
Shareholder Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies is Fair to Shareholders - FOMX, CISN, PEGI, AXE

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

FOMX : 3.41 (+0.29%)
CISN : 10.12 (-0.78%)
PEGI : 27.33 (+0.13%)
AXE : 85.74 (+0.54%)
Foamix (FOMX) Reports Q3 Loss, Misses Revenue Estimates

Foamix (FOMX) delivered earnings and revenue surprises of -20.59% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

FOMX : 3.41 (+0.29%)
Foamix: 3Q Earnings Snapshot

REHOVOT, Israel (AP) _ Foamix Pharmaceuticals Ltd. (FOMX) on Monday reported a loss of $23.2 million in its third quarter.

FOMX : 3.41 (+0.29%)
Foamix Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs...

FOMX : 3.41 (+0.29%)
Foamix Announces Issuance of New U.S. Patent for Compositions Combining a Retinoid and a Tetracycline Antibiotic

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,463,742,...

FOMX : 3.41 (+0.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Trade FOMX with:

Business Summary

Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company's lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe...

See More

Key Turning Points

2nd Resistance Point 3.54
1st Resistance Point 3.47
Last Price 3.41
1st Support Level 3.31
2nd Support Level 3.22

See More

52-Week High 4.48
Fibonacci 61.8% 3.52
Last Price 3.41
Fibonacci 50% 3.22
Fibonacci 38.2% 2.93
52-Week Low 1.97

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar